Rafael holdings reports first quarter fiscal 2022 financial and operating results

Newark, n.j., dec. 15, 2021 (globe newswire) -- rafael holdings, inc., (nyse: rfl), an early-stage cancer and immune metabolism therapeutics company, today reported its financial results for the first quarter of its 2022 fiscal year, the three months ended october 31, 2021. we have made significant progress in aligning our leadership team and capabilities, with ameet mallik set to transition his chief executive officer responsibilities to chairman, howard jonas, as of february 1, 2022, patrick fabbio assuming the position of president, in addition to continuing as chief financial officer, and dr. mimi huizinga assuming the position of head of research and development in addition to continuing as chief medical officer. we are well funded to advance our early-stage research and development programs in collaboration with world class scientific advisors.
RFL Ratings Summary
RFL Quant Ranking